🇺🇸 FDA
Pipeline program

A study to test whether BI 456906 (survodutide) influences the amount of bupropion, caffeine and midazolam in the blood in people with overweight or obesity

1404-0008

Phase 1 other active

Quick answer

A study to test whether BI 456906 (survodutide) influences the amount of bupropion, caffeine and midazolam in the blood in people with overweight or obesity for Overweight, Obesity is a Phase 1 program (other) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Boehringer Ingelheim International GmbH
Indication
Overweight, Obesity
Phase
Phase 1
Modality
other
Status
active

Clinical trials